Lynk Pharmaceuticals Competitors and Similar CompaniesClear all
Rigel Pharmaceuticals's competitors and similar companies include BridgeBio.
 Rigel Pharmaceuticals Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases. |  BridgeBio BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases. | |
Founding Date | Founding Date 1996 | Founding Date 2014 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations South San Francisco, US HQ | Locations Palo Alto, US HQ |
Employees | Employees 1633% increase | Employees 24863% increase |
Valuation ($) | Valuation ($) 256 m | Valuation ($) 4.6 b |
Financial | ||
Revenue (est.) | Revenue (est.) $294.3m (FY, 2025) | Revenue (est.) $502.1m (FY, 2025) |
Cost of goods | Cost of goods $19.6m (FY, 2025) | Cost of goods $21m (FY, 2025) |
Gross profit | Gross profit $274.7m (FY, 2025) | Gross profit $481.1m (FY, 2025) |
Net income | Net income $367m (FY, 2025) | Net income ($732.9m) (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 130m | Total funding raised $ 474.2m |
For sources of this data, please see the company profile
View Company Profiles
BridgeBio
HQ
Palo Alto, US
Employees
248
BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.
View company